Business

Transcatheter Technologies Wins ‘Best Business Pitch’ Award at “German Venture Day” for Its Prosthetic Aortic Heart Valve, Intrinsic to World’s First ‘Truly Repositionable’ TAVI Device, TRINITY

Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.

“This 3rd-generation TRINITY technology could be a game-changer for TAVI.” Prof. Dr. Christian Hengstenberg, MD, German Heart Center, Munich

REGENSBURG, Germany–(BUSINESS WIRE)–March 7, 2014–

Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system-TRINITY-announced today that its CEO, Wolfgang Goetz, M.D., Ph.D., was awarded top prize for “best business pitch” in the 4th annual “German Venture Day” (GVD) organized by Private Equity Forum NRW.

Transcatheter Technologies recently announced the successful 30-day follow-up results of a pilot study of its TRINITY TAVI system that is designed to be the world’s first ‘truly repositionable’ and, therefore, best TAVI system.

“Unlike second-generation TAVI systems on the market today, the Trinity aortic valve is designed to be positioned precisely or even repositioned, even after full implantation, in a safe and simple manner,” said principal investigator Prof. Dr. Christian Hengstenberg, a cardiologist at the German Heart Center, Munich, Germany, with no financial interest or arrangement or affiliation with Transcatheter Technologies. “In our study, Trinity’s novel sealing cuff continues to provide outstanding follow-up results without PVL (paravalvular leak), an all-too-frequent complication of TAVI. Equally important, the TRINITY aortic valve is designed to reduce the risk of atrio-ventricular (AV) block significantly through supra-annular positioning of the TRINITY valve.”

“Winning this competition enables us to get on the radar screen of investors who may not know us yet,” said Wolfgang Goetz, M.D., Ph.D., CEO, a cardiac surgeon by training. “The big issue with currently marketed second-generation TAVI systems is that they cannot be truly repositioned once fully implanted. TRINITY, however, is designed to solve this critically important issue and thereby potentially reduce the undesirable side consequences of paravalvular leak PVL,” added Dr. Goetz.

“With TRINITY, once our valve is completely expanded and anchored above the annulus, a cardiologist can fully evaluate the valve’s function to determine whether it needs to be repositioned, retrieved, or kept in the same position. This feature and its supra-annular anchoring are absolutely unique to TRINITY, which is why we have positioned TRINITY as a Third-Generation TAVI System. We are very pleased that investors at the GVD competition understood the enormous opportunity ahead of us and applauded our plan for seizing this opportunity.”

About Transcatheter Technologies GmbH

Transcatheter Technologies GmbH is a privately held medical device company founded in 2009 and headquartered in Regensburg, Germany. The TRINITY aortic valve prosthesis is comprised of a bovine pericardium valve with porcine pericardium-sealing cuff that is mounted on a self-expanding Nitinol frame. The TRINITY aortic valve prosthesis is pre-mounted on a detachable catheter tip. TRINITY’s unique features enable controlled positioning and true repositioning without foreshortening. The valve prosthesis is protected during folding of the stent. This Zero Pressure CrimpingTM is expected to improve valve durability and broaden the application of transcatheter valve implantations across a larger patient population.

CAUTION: TRINITY is not approved for use in the United States.

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108

More information:

Powered by VBProfiles


We're studying conversion rate optimization. Take our quick survey and we'll share the results with you.